Medication info

Ilsung Sitagliptin Tablet 50 mg (Sitagliptin Phosphate)

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate›62.04mg / 1 tablet
Manufacturer / importer
Ilsung IS Co., Ltd.
Appearance
Biconvex round film-coated tablet, light beige in color
Packaging
30 tablets/box [(10 tablets/PTP x 3 packages)]
Approval status
Expired

MFDS item code 201503329 · Approved 2015.05.29

This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function before and periodically after administration of this medicine is recommended. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Ilsung IS Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It may be given alone to patients who need initial blood sugar control. If adequate effect is not achieved with monotherapy, it may be combined with Metformin. Additionally, if blood sugar control is difficult with monotherapies such as sulfonylureas, Metformin, thiazolidinediones, or insulin, this medication may be added. Even after combination therapy with multiple drugs, this medication may be added to improve effectiveness. Overall, this medication is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function before and periodically after administration of this medicine is recommended. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication can rarely cause serious allergic reactions. If symptoms such as sudden rash, difficulty breathing, or swelling of the face or neck occur after taking this medication, usage should be discontinued immediately and a physician should be consulted. Acute pancreatitis may occur during treatment with this medication, so immediate medical attention is necessary if symptoms such as sudden abdominal pain, vomiting, or nausea appear. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis, and usage should be avoided in cases of severe allergy to this medication or its components. Patients with impaired kidney function should have their dosage adjusted based on their renal function, as the drug may remain in the body longer. It is important to conduct kidney function tests before and during treatment. Symptoms of hypoglycemia may occur when this medication is taken alone or in combination with other antidiabetic agents, so blood sugar should be monitored frequently, and appropriate action should be taken if hypoglycemia symptoms occur. During treatment with this medication, symptoms such as headache, upper respiratory infection, nasopharyngitis, diarrhea, nausea may occur. If symptoms are severe or persist for a long time, consultation with medical personnel is recommended. In particular, when used in conjunction with insulin or sulfonylureas, the risk of hypoglycemia is increased; thus, adjustments to the dosages of these medications may be necessary. This medication is not recommended for use in pregnant or breastfeeding women, so patients should consult their physician if they plan to become pregnant or are currently pregnant. Safety and efficacy in children and adolescents have not been established, so use is not advised. Elderly patients may have reduced kidney function; thus, dosage adjustment and kidney function testing may be required. In case of overdose, immediate treatment at a medical institution is necessary, and this medication may be partially removed by hemodialysis. Additionally, if symptoms such as joint pain or skin blisters occur during treatment with this medication, the physician should be notified immediately, and discontinuation of the medication may be necessary. This medication has relatively few interactions with other specific medications; however, caution is needed when taken with certain drugs such as digoxin or cyclosporine. Lastly, regular medical check-ups should be maintained during treatment with this medication to closely observe any adverse reactions or changes in symptoms.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory infection
  • headache
  • diarrhea
  • abdominal pain
Show 30 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • blistering dermatosis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • elevated low-density lipoprotein
  • hyperglycemia
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture ingress, ideally at room temperature between 1 degree and 30 degrees Celsius. Proper storage can help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Biconvex round film-coated tablet, light beige in color

Package unit

30 tablets/box [(10 tablets/PTP x 3 packages)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.